Pharmaceuticals Saudi Arabia

Saudi Arabia Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Saudi Arabia Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $39.7 Mn Placeholder estimate
Estimate 2025 $48.3 Mn 1.7% of the global market
Projected 2034 $282.8 Mn 485.6% Adds $234.5 Mn over 9 forecast years
CAGR 2025–2034 21.7% Faster than 89% of 180 Pharmaceuticals markets here
Key players 4
  • Saudi Arabia is 1.68% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $48.3 Mn.
  • Fastest growing: Saudi Arabia (this report) at 21.7% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$234.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $39.7 Mn — —
2025 (base) $48.3 Mn +$8.6 Mn —
2026 (forecast) $58.8 Mn +$10.5 Mn +21.7%
2027 (forecast) $71.5 Mn +$12.8 Mn +48.1%
2028 (forecast) $87.0 Mn +$15.5 Mn +80.2%
2029 (forecast) $105.9 Mn +$18.9 Mn +119.4%
2030 (forecast) $128.9 Mn +$23.0 Mn +167%
2031 (forecast) $156.9 Mn +$28.0 Mn +224.9%
2032 (forecast) $190.9 Mn +$34.0 Mn +295.4%
2033 (forecast) $232.3 Mn +$41.4 Mn +381.2%
2034 (forecast) $282.8 Mn +$50.4 Mn +485.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Saudi Arabia Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$48.3 Mn placeholder estimate
Forecast, 2034$282.8 Mn placeholder estimate
Growth (CAGR), 2025–203421.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in Saudi ArabiaSFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Saudi Arabia Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: Saudi Arabia Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $39.7 Mn in 2024, $48.3 Mn in 2025 and $282.8 Mn in 2034, 21.7% CAGR.
Saudi Arabia Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Saudi Arabia Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in Saudi Arabia

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Saudi Arabia

Long-Acting HIV Treatment in Saudi Arabia: rules, payment and health figures

The Saudi Food and Drug Authority (SFDA) registers medicines before sale.⁠[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).⁠[2] New HIV infections: 1,300 people in 2025, the latest WHO figure for Saudi Arabia.⁠[3]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Council of Health Insurance. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, New HIV infections (people). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

Saudi Arabia compared

  • New HIV infections: 1,300 people (2025). World: 1.2 million people (2025). Highest of the 6 countries we cover in Middle East.[1]
  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 10 countries we cover in Middle East.[2]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 10 countries we cover in Middle East.[3]

[1] WHO Global Health Observatory, New HIV infections (people). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in Saudi Arabia?
Placeholder estimate: about $48.3 Mn in 2025, rising to about $282.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Saudi Arabia growing?
Placeholder estimate: about 21.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Saudi Arabia?
The Saudi Food and Drug Authority (SFDA) registers medicines before sale. Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
What does WHO report for Saudi Arabia?
New HIV infections: 1,300 people in 2025, the latest WHO figure. Source: WHO Global Health Observatory, New HIV infections (people). Retrieved 20 Nov 2026.
How many people in Saudi Arabia are 65 or older?
3.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Saudi Arabia

See all

Related on hiv and infectious diseases

See the topic